 |
|
High-Dose Recombinant Interleukin-2 in Advanced Cutaneous T-Cell Lymphoma
Jean Pierre Marolleau, MD;
Michel Baccard, MD;
Béatrice Flageul, MD;
Michel Rybojad, MD;
Liliane Laroche, MD;
Olivier Vérola, MD;
Maud Brandely, MD;
Patrice Morel, MD;
Christian Gisselbrecht, MD
Arch Dermatol. 1995;131(5):574-579.
Abstract
| |
Background and Design
Treatment of cutaneous T-cell lymphoma is still a difficult challenge, once the usual therapies (topical chemotherapy, phototherapy, radiation therapy, and chemotherapy) have proved to be unsuccessful. New therapies, mostly immunotherapies, are currently under investigation. The use of recombinant interleukin-2 has already been evaluated in hematopoietic malignancies. We decided to treat patients with advanced cutaneous T-cell lymphoma relapsing or progressing in spite of the usual treatments with high-dose recombinant interleukin-2. Seven patients (three with mycosis fungoides, three with Sézary syndrome, and one with nonepidermotropic large-cell cutaneous lymphoma) were included in this open study. They were scheduled to receive recombinant interleukin-2 at a dose of 20x106 IU/m2 per day, administered by continuous infusion during three fortnightly induction cycles and five monthly consolidation cycles.
Results
Three complete responses (two responses to mycosis fungoides; one response to large-cell lymphoma) and two partial responses were obtained. The clinical response appeared after the first cycle of treatment in the good responders. The complete responses are still ongoing 33, 28, and 6 months after completion of recombinant interleukin-2 therapy and without any further treatment. Sequential immunophenotypic studies showed an increase of the CD1+ cells in the dermal infiltrates. No significant modification of natural killer or cytotoxic T cells could be seen.
Conclusions
Despite our low number of cases, our results clearly show that some advanced cutaneous T-cell lymphomas can benefit from high-dose recombinant interleukin-2 therapy. Further studies are necessary to determine the exact place of recombinant interleukin-2 in the therapeutic arsenal of cutaneous T-cell lymphoma.
(Arch Dermatol. 1995;131:574-579)
Author Affiliations
From the Departments of Hematology (Drs Marolleau and Gisselbrecht), Dermatology-Prof Morel (Drs Baccard, Rybojad, and Morel), Dermatology-Prof Dubertret (Dr Flageul), Anatomopathology (Dr Vérola), Hôpital Saint Louis, Paris, France; the Department of Dermatology, Hôpital Avicenne, Bobigny, France (Dr Laroche); and Roussel UCLAF Laboratory, Romainville, France (Dr Brandely).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Durable Clinical, Cytogenetic, and Molecular Remissions After Allogeneic Hematopoietic Cell Transplantation for Refractory Sezary Syndrome and Mycosis Fungoides
Molina et al.
JCO 2005;23:6163-6171.
ABSTRACT
| FULL TEXT
Prognostic Value of Blood Eosinophilia in Primary Cutaneous T-Cell Lymphomas
Tancrede-Bohin et al.
Arch Dermatol 2004;140:1057-1061.
ABSTRACT
| FULL TEXT
Bexarotene Is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial Results
Duvic et al.
JCO 2001;19:2456-2471.
ABSTRACT
| FULL TEXT
Primary Cutaneous T-Cell Lymphoma: Review and Current Concepts
Siegel et al.
JCO 2000;18:2908-2925.
ABSTRACT
| FULL TEXT
Interleukin-12 Therapy of Cutaneous T-Cell Lymphoma Induces Lesion Regression and Cytotoxic T-Cell Responses
Rook et al.
Blood 1999;94:902-908.
ABSTRACT
| FULL TEXT
Middle-Term Evolution of Patients With Advanced Cutaneous T-Cell Lymphoma Treated With High-Dose Recombinant Interleukin-2
Baccard et al.
Arch Dermatol 1997;133:656-656.
ABSTRACT
Rational Therapy for Cutaneous T-Cell Lymphomas in the 1990s: Fact or Fancy?
Bunn
Arch Dermatol 1995;131:603-605.
ABSTRACT
|
